A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults1-3

Journal of Nutrition

Volumn 143, Issue 3, 2013, Pages 324-331

  Vulevic, Jelena ^a   Juric, Aleksandra ^a   Tzortzis, George ^a   Gibson, Glenn R ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; GALACTOSE OLIGOSACCHARIDE; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MALTODEXTRIN; PREBIOTIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATOPOBIUM; BACTEROIDES; BETAPROTEOBACTERIA; BIFIDOBACTERIACEAE; BLOOD CELL COUNT; BLOOD SAMPLING; CLINICAL ARTICLE; CLOSTRIDIUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DESULFOVIBRIO; DOUBLE BLIND PROCEDURE; ENTEROCOCCUS; FAECALIBACTERIUM PRAUSNITZII; FECES ANALYSIS; FECES MICROFLORA; FEMALE; HUMAN; IMMUNITY; INFLAMMATION; INTESTINE FLORA; LACTOBACILLUS; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SALIVA ANALYSIS;

ADULT; BACTERIA; BIFIDOBACTERIUM; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FECES; FEMALE; GALACTOSE; HUMANS; IMMUNITY; IMMUNOGLOBULIN A; INFLAMMATION; INSULIN; LEUKOCYTE L1 ANTIGEN COMPLEX; LIPIDS; MALE; METABOLIC SYNDROME X; METAGENOME; MIDDLE AGED; OLIGOSACCHARIDES; OVERWEIGHT; PREBIOTICS; RISK FACTORS;

EID: 84874720592     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.112.166132     Document Type: Article

References (52)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
2. Wildman RP. Healthy obesity. Curr Opin Clin Nutr Metab Care. 2009;12:438-43.
3. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-7.
4. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005;102:11070-5.
5. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007;449:804-10.
6. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153-8.
7. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-31.
8. Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin NutrMetab Care. 2007;10:729-34.
9. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101: 15718-23.
10. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996;38:916-9.
11. Fuller R. Probiotics: growth-promoting factors produced by microorganisms. Science. 1989;147:747-8.
12. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125: 1401-12.
13. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104: Suppl2:S1-63.
14. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15:1546-58.
15. The IDF consensus worldwide definition of the metabolic syndrome [cited 2012 Aug 15]. Available from: www.idf.org.
16. Vulevic J, Drakoularakou A, Yaqoob P, Tzortzis G, Gibson GR. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr. 2008;88:1438-46.
17. Manz W, Amann R, Ludwig W, Vancanneyt M, Schleifer KH. Application of a suite of 16s rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophage-flavobacterbacteroides in the natural environment. Microbiology. 1996;142:1097-106.
18. Langendijk PS, Schut F, Jansen GJ, Raangs GC, Kamphuis GR, Wilkinson MH, Welling GW. Quantitative fluorescent in situ hybridisation of Bifidobacterium spp. with genus specific 16S rRNA targeted probes and its application in fecal samples. Appl Environ Microbiol. 1995;61:3069-75.
19. Harmsen HJM, Elfferich P, Schut F, Welling GW. A 16S rRNA-targeted probe for detection of lactobacilli and enterococci in faecal samples by fluorescent in situ hybridisation. Microb Ecol Health Dis. 1999;11: 3-12.
20. Franks AH, Harmsen HJM, Raangs GC, Jansen GJ, Schut F, Welling GW. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol. 1998;64:3336-45.
21. Devereux R, Kane MD, Winfrey J, Stahl DA. Genus-and group-specific hybridisation probes for determinative and environmental studies of sulphate-reducing bacteria. Syst Appl Microbiol. 1992;15:601-9.
22. Harmsen HJM, Wildeboer-Veloo ACM, Grijpstra J, Knol J, Degener JE, Welling GW. Development of 16S rRNA-based probes for the Coriobacterium group and the Atopobium cluster and their application for enumeration of Coriobacteriaceae in human feces from volunteers of different ages. Appl Environ Microbiol. 2000;66:4523-7.
23. Harmsen HJ, Raangs GC, He T, Degener JE, Welling GW. Extensive set of 16S rRNA-based probes for detection of bacteria in human feces. Appl Environ Microbiol. 2002;68:2982-90.
24. Manz W, Amann R, Ludwig W, Wagner M, Schleifer KH. Phylogenetic oligodeoxynucleotide probes for the major subclasses of Proteobacteria: problems and solutions. Syst Appl Microbiol. 1992;15:593-600.
25. Walker AW, Duncan SH, McWilliam Leitch EC, Child MW, Flint HJ. pH and peptide supply can radically alter bacterial populations and short chain fatty acid ratios within microbial communities from the human colon. Appl Environ Microbiol. 2005;71:3692-700.
26. Suau A, Rochet V, Sghir A, Gramet G, Brewaeys S, Sutren M, Rigottier-Gois L, Doré J. Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst Appl Microbiol. 2001;24:139-45.
27. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56: 1761-72.
28. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increase of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50: 2374-83.
29. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement in gut permeability. Gut. 2009; 58:1091-103.
30. Winkler P, Ghadimi D, Schrezenmeir J, Kraehenbuhl JP. Molecular and cellular basis of microflora-host interactions. J Nutr. 2007;137:756S-72S.
31. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3:213-23.
32. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemiainduced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470-81.
33. Waldram A, Holmes E,Wang Y, Rantalainen M, Wilson ID, Tuohy KM, McCartney AL, Gibson GR, Nicholson JK. Top-down systems biology modelling of host metabotype-microbiome associations in obese rodents. J Proteome Res. 2009;8:2361-75.
34. Zhang C, Zhang M, Wang S, Han R, Cao Y, Hua W, Mao Y, Zhang X, Pang W, Wei C, et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 2010;4:232-41.
35. Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, Hardt PD. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18:190-5.
36. Kelly-Quagliana KA, Nelson PD, Buddington RK. Dietary oligofructose and inulin modulate immune function in mice. Nutr Res. 2003;23:257-67.
37. Hosono A, Ozawa A, Kato R, Ohnishi Y, Nakanishi Y, Kimura T, Nakamura R. Dietary fructooligosaccharides induce immunoregulation of intestinal IgA secretion by murine Peyer's patch cells. Biosci Biotechnol Biochem. 2003;67:758-64.
38. Vos AP, M'Rabet L, Stahl B, Boehm G, Garssen J. Immune-modulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol. 2007;27:97-140.
39. Hoyles L, Vulevic J. Diet, immunity and functional foods. Adv Exp Med Biol. 2008;635:79-92.
40. Depeint F, Tzortzis G, Vulevic J, Ianson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, cross-over, placebocontrolled intervention study. Am J Clin Nutr. 2008;87:785-91.
41. Silk DBA, Davies A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508-18.
42. Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma. 2006;61:650-7.
43. Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D, Ogra PL. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci. 2004;49:579-89.
44. Wang ZT, Yao Y, Xiao G, Sheng ZY. Risk factors of development of gutderived bacterial translocation in thermally injured rats. World J Gastroenterol. 2004;10:1619-24.
45. Ruan X, Shi H, Xia G, Xiao Y, Dong J, Ming F, Wang S. Encapsulated bifidobacteria reduced bacterial translocation in rats following hemorrhagic shock and resuscitation. Nutrition. 2007;23:754-61.
46. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009;89:1751-9.
47. Genta S, Cabrera W, Habib N, Pons J, Carillo IM, Grau A, Sanchez S. Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr. 2009;28:182-7.
48. Nguyen TDT, Kang JH, Lee MS. Characterisation of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterollowering effects. Int J Food Microbiol. 2007;113:358-61.
49. Causey JL, Feir TGJM, Gallaher DD, Tungland BC, Slavin JL. Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal environment in hypercholesterolemic men. Nutr Res. 2000;20: 191-201.
50. Luo J, van Ypersalle M, Rizkalla SW, Rossi F, Bornet FRJ, Slama G. Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in Type 2 diabetics. J Nutr. 2000;130:1572-7.
51. Greany KA, Bonorden MJL, Halmiton-Reeves JM, McMullen MH, Wangen KE, Phipps WR, Feir TGJ, Thomas W, Kurzer MS. Probiotic capsules do not lower plasma lipid in young women and men. Eur J Clin Nutr. 2008;62:232-7.
52. Ooi LG, Liong MT. Cholesterol lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci. 2010;11:2499-522.